Tina Vilsbøll

Tina Vilsbøll

Clinical Professor

Member of:

  • Internal Medicine: Endocrinology


Publication year:
All
1 - 9 out of 9Page size: 10
  1. 2010
  2. Published

    Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis

    Knop, Filip Krag, Vilsbøll, Tina, Larsen, S., Madsbad, Sten, Holst, Jens Juul & Krarup, T. M., 24 Sep 2010, In: Regulatory Peptides. 164, 2-3, p. 144-50 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency

    Knop, Filip Krag, Vilsbøll, Tina, Lund, A., Krarup, T., Holst, Jens Juul & Hornum, Mads, 6 Sep 2010, In: Journal of the Pancreas. 11, 5, p. 489-91 3 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes

    Christensen, M., Knop, Filip Krag, Vilsbøll, Tina, Aaboe, K., Holst, Jens Juul, Madsbad, Sten & Krarup, T., 9 Aug 2010, In: Regulatory Peptides. 163, 1-3, p. 96-101 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects

    Hansen, K. B., Vilsbøll, Tina, Bagger, J. I., Holst, Jens Juul & Knop, Filip Krag, 1 Jul 2010, In: The Journal of clinical endocrinology and metabolism. 95, 7, p. 3309-17 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

    Hare, K. J., Vilsbøll, Tina, Asmar, M., Deacon, Carolyn F., Knop, Filip Krag & Holst, Jens Juul, 1 Jul 2010, In: Diabetes. 59, 7, p. 1765-70 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes

    Hare, K. J., Vilsbøll, Tina, Holst, Jens Juul & Knop, Filip Krag, 1 Apr 2010, In: American Journal of Physiology: Endocrinology and Metabolism. 298, 4, p. E832-7 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

    Vilsbøll, Tina, Rosenstock, J., Yki-Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Vendersbo, R. K., Amatruda, J. M., Engel, S. S. & Katz, L., 1 Feb 2010, In: Diabetes, Obesity and Metabolism. 12, 2, p. 167-77 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review

    Hansen, K. B., Vilsbøll, Tina & Knop, Filip Krag, 1 Jan 2010, In: Diabetes, Metabolic Syndrome and Obesity. 3, p. 155-63 9 p.

    Research output: Contribution to journal › Review › Research › peer-review

  10. Published

    Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose- and non-glucose-induced insulin secretion in patients with type 2 diabetes mellitus

    Aaboe, K., Knop, Filip Krag, Vilsbøll, Tina, Deacon, Carolyn F., Holst, Jens Juul, Madsbad, Sten & Krarup, T., 2010, In: Diabetes, Obesity and Metabolism. 12, 4, p. 323-333 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

ID: 33056950